Search Results
1
Study Matches
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
This is a phase 2/3, multi-center, randomized, double-blind, study for patients with moderate to severe Crohn's disease. Subjects with refractory CD or who are intolerant to at least one current therapy will be considered. The study consists of four substudies. They are designed to investigate efficacy, safety, tolerability of etrasimod as therapy for CD.
Zvjezdana (stella) Sever Chroneos at zchroneos1@pennstatehealth.psu.edu or 717-531-8259
All
18 year(s) or older
NCT04173273
Digestive Systems & Liver Disease